Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

Biologics Resources

Find information about our functional bioassays for biologic drug discovery. View scientific presentations and posters with the latest technology and data to help with your research needs.

Scientific Presentations


Development of Bioluminescent No-wash Fc Gamma Receptor Binding Immunoassay to Guide the Development of Antibody Therapeutics

Presented by Nidhi Nath, Promega Corporation

Download PDF


Quantitative PBMC ADCC Bioassay and ADCC Reporter Bioassays for Immunotherapy and SARS-CoV-2 Monoclonal Antibody Development

Presented by Jeff Nelson, Promega Corporation

Download PDF


HiBiT: A Tiny Tag to Assess MOA-based CAR-T Cell Potency

Presented by Mei Cong, Promega Corporation

Download PDF


MoA-Based Potency Bioassays for Immunotherapy Programs Targeting the TIGIT/CD112R/CD226 Axis

Presented by Kai Hillman, Promega Corporation

Download PDF


Reproducible, MoA-reflecting Reporter-based Bioassays to Enable Discovery and Development of Cytokine Therapeutics

Presented by Vanessa Ott, Promega Corporation

Download PDF


Developing a New HiBiT-PsVLP-based Neutralization Assay Platform for Anti-SARS-CoV-2 Therapy and Beyond

Presented by Jey Cheng, Sr Research Scientist, Promega Corporation

This presentation from BEBPA US 2022 introduces new assays to measure neutralizing activity and Fc effector function for SARS-CoV-2 antibodies. You will learn about:

  • A new platform: HiBiT-Pseudotyped Virus-Like Particles (HiBiT- PsVLP)
  • Rapid method for measuring neutralizing antibody activity, including in human sera
  • Ability to detect differences in antibody neutralization to viral variants
Download PDF


Applying Cell-based Assays to Evaluate the Complex Biology for Drug Candidates Targeting Macrophage -directed Therapies

Presented by Jey Cheng, Sr Research Scientist, Promega Corporation

This presentation supports Macrophage-directed Therapies. You will learn about:

  • Measuring the antibody-dependent cellular phagocytosis (ADCP)
  • Distinguishing the mechanisms of action between Fc-active or Fc-inactive CD47 antibodies
  • Evaluating CD47/SIRPa targeting therapy as monotherapy or combination therapy with antibodies of ADCP MoA
Download PDF


SARS-CoV-2 Bioassays

Presented by Jey Cheng, Sr Research Scientist, Promega Corporation

This presentation introduces bioassays developed to address the two major mechanisms of action for SARS-CoV-2 antibodies. You will learn about:

  • The SARS-CoV-2 HiBiT-PsVLP Assay for neutralization activity
  • ADCC/ADCP Reporter Bioassays for antibody Fc effector function
Download PDF


Bioluminescent Bioassays: From Reporter Cell Lines to Primary Cells

Presented by Jey Cheng, Sr Research Scientist, Promega Corporation

This presentation introduces our portfolio expansion into primary cell-based assays for immunotherapeutic drug development. You will learn about:

  • Using HiBiT-based target cells for ADCC and TDCC assays
  • NanoBiT immunoassays for measuring cytokine release 
Download PDF


Novel Bioluminescent Bioassays for the Discovery and Development of T Cell Redirecting Cancer Therapies

Presented by Julia Gilden, Sr Research Scientist, Promega Corporation

This presentation will discuss new bioluminescent tools to expedite the development of T cell-redirecting cancer therapies. You will learn about:

  • NanoBiT-based assay platforms that can quantitatively measure the potency of CD3 bispecific antibodies or BiTEs to induce T cell-dependent target cell killing and cytokine production.
  • TCRαβ-null reporter cell lines that can be used to screen transgenic TCRs against specific tumor antigen targets. 
Download PDF

See lists of peer-reviewed publications that used our reporter bioassays for viral vaccine research and immunotherapy drug development assays including mAb therapeutics, bispecific antibodies, oncolytic virus therapy, cancer vaccines, gene therapy and biosimilars.

Bioassays for BiologicsViral Vaccine Development

Scientific Posters


Developing a Bioluminescent PBMC ADCC Assay for the Discovery and Characterization of Therapeutic Antibodies
Presented by Jey Cheng, Sr. Research Scientist

Download PDF

jamison-grailer-125 Cell-Based Reporter Bioassays for Development of Fc-Functional and Fc-Silent SIRPa/CD47 Checkpoint Inhibitors

Presented by Jamison Grailer, Sr Research Scientist

Download PDF


Quantitative Cell-Based Bioassays to Advance Immunotherapy Programs Targeting Immune Checkpoint Receptors
Presented by Jamison Grailer, Sr Research Scientist

Download PDF

jeff-nelson-125x125 A No-Wash, Rapid FcRn Binding Immunoassay to Guide the Design and Development of Antibody Therapeutics

Presented by Jeff Nelson, Product Manager

Download PDF

New Products

PBMC ADCC Bioassay

Perform your ADCC method bridging studies with the new PBMC ADCC Bioassay, featuring pre-qualified PBMCs. The assay offers improved consistency and robustness for measuring ADCC. Each assay includes ADCC-qualified PBMC effector cells and a choice of popular target cells expressing a HiBiT fusion protein. The simple, add-mix-read format uses bioluminescent detection for maximum sensitivity.

Learn More
In this video interview, Senior Research Scientist Jey Cheng answers common questions about the PBMC ADCC Bioassay.

Lumit™ Immunoassays

Replace conventional immunoassays, such as Western blots and ELISAs, with new Lumit™ Immunoassays. These assays offer direct luminescence measurement in cell culture, broad dynamic range, and can be completed in as little as 30 minutes.

Lumit™ Immunoassays are available for a range of applications, including protein phosphorylation and pathway analysis, FcRn binding, cytokine detection, metabolite research, and more. You can also build your own Lumit™ immunoassays with our labeling and detection kits.

Learn More

Lumit immunoassay principle

General principle of a Lumit™ Immunoassay. Antibodies are chemically labeled with the small and large subunits of NanoLuc® Luciferase, known as SmBiT and LgBiT, respectively. In the presence of an analyte, the two antibodies come into close proximity, allowing SmBiT and LgBiT to form an active enzyme and generate a bright luminescence signal.